Table 2 Clinical characteristics and outcomes of patients with CCNE1-amplified tumors in the “Discovery-TNBC” cohort
From: CCNE1 amplification is associated with poor prognosis in patients with triple negative breast cancer
Patient ID | Age | Stage | (Neo)Adjuvant chemotherapy | Response to neoadjuvant chemotherapy | Adjuvant radiation | RFS (months) | OS (months) |
|---|---|---|---|---|---|---|---|
1 | 50 | I | Declined | N/A | No | 58 | N/A |
2 | 50 | III | TAC | ypT2N0Mx | No | 11 | 23 |
3 | 46 | III | AC Carbo/nab-paclitaxel | ypT3N1Mx | Yes | 24 | 55 |
4 | 36 | III | AC-T | ypT0N1Mx | Yes | 13 | 18 |
5 | 35 | III | Carbo/taxol | ypT3N2aMx | Yes | 3 | 21 |
6 | 46 | III | Carbo/taxol | ypT3N3aMx | Yes | 13 | 43 |
7 | 50 | II | Docetaxel, cisplatin | ypT1N1Mx | Yes | 8 | 15 |
8 | 46 | III | Carbo/taxol, AC | ypT2N2aMx | Yes | 11 | 20 |
9 | 36 | II | Carbo/nab-paclitaxel | ypT1cN0Mx | Yes | 8 | 24 |
10 | 55 | III | AC-T (adjuvant) | pT4N2aMx | No | 46 | 60 |
11 | 46 | II | Carbo/taxol (adjuvant) | pT2N1Mx | No | 21 | 34 |
12 | 53 | III | AC-T | ypT1N1aMx | No | 9 | 16 |
13 | 48 | II | TC | ypT1cN1Mx | Yes | 3 | 38 |